Cristel Sørensen Hjortshøj

Cristel Sørensen Hjortshøj

Auto-generated profile, based on publicly available information

Cristel Sørensen Hjortshøj

Department of Cardiology, Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2017 in Circulation
Verified
Journal Article
Open access
PDF file
AKAleksander Kempny
Aleksander Kempny
CHCristel Sørensen Hjortshøj
Cristel Sørensen Hjortshøj
HGHong Gu
Hong Gu
WLWei Li
Wei Li
AOAlexander R. Opotowsky
Alexander R. Opotowsky
MGMichael A. Gatzoulis
Michael A. Gatzoulis
Background: Eisenmenger syndrome is associated with substantial morbidity and mortality. There is no consensus, however, on mortality risk stratification. We aimed to investigate survival and predictors of death in a large, contemporary cohort of Eisenmenger syndrome patients. Methods: In a multicenter approach, we identified adults with Eisenmenger syndrome under follow-up between 2000 and 2015. We examined survival and its association with clinical, electrocardiographic, echocardiographic, and laboratory parameters. Results: We studied 1098 patients (median age, 34.4 years; range, 16.1–84.4 years; 65.1% female; 31.9% with Down syndrome). The majority had a posttricuspid defect (n=643, 58.6%), followed by patients with a complex (n=315, 28.7%) and pretricuspid lesion (n=140, 12.7%). Over a median follow-up of 3.1 years (interquartile range, 1.4–5.9), allowing for 4361.6 patient-years observation, 278 patients died and 6 underwent transplantation. Twelve parameters emerged as significant predictors of death on univariable analysis. On multivariable Cox regression analysis, only age (hazard ratio [HR], 1.41/10 years; 95% confidence interval [CI], 1.24–1.59; P <0.001), pretricuspid shunt (HR, 1.56; 95% CI, 1.02–2.39; P =0.041), oxygen saturation at rest (HR, 0.53/10%; 95% CI, 0.43–0.65; P <0.001), presence of sinus rhythm (HR, 0.53; 95% CI, 0.32–0.88; P =0.013), and presence of pericardial effusion (HR, 2.41; 95% CI, 1.59–3.66; P <0.001) remained significant predictors of death. Conclusions: There is significant premature mortality among contemporary adults with Eisenmenger syndrome. We report, herewith, a multivariable mortality risk stratification model based on 5 simple, noninvasive predictors of death in this population.

18 April 2017 in European Heart Journal
Verified
Journal Article
Open access
PDF file
CHCristel M. Sørensen Hjortshøj
Cristel M. Sørensen Hjortshøj
AKAleksander Kempny
Aleksander Kempny
AJAnnette Schophuus Jensen
Annette Schophuus Jensen
KSKeld Sørensen
Keld Sørensen
ENEdit Nagy
Edit Nagy
LSLars Søndergaard
Lars Søndergaard
Eisenmenger syndrome (ES) is associated with considerable morbidity and mortality. Therapeutic strategies have changed during the 2000s in conjunction with an emphasis on specialist follow-up. The aim of this study was to determine the cause-specific mortality in ES and evaluate any relevant changes between 1977 and 2015. This is a retrospective, descriptive multicentre study. A total of 1546 patients (mean age 38.7 ± 15.4 years; 36% male) from 13 countries were included. Cause-specific mortality was examined before and after July 2006, ‘early’ and ‘late’, respectively. Over a median follow-up of 6.1 years (interquartile range 2.1–21.5 years) 558 deaths were recorded; cause-specific mortality was identified in 411 (74%) cases. Leading causes of death were heart failure (34%), infection (26%), sudden cardiac death (10%), thromboembolism (8%), haemorrhage (7%), and peri-procedural (7%). Heart failure deaths increased in the ‘late’ relative to the ‘early’ era (P = 0.032), whereas death from thromboembolic events and death in relation to cardiac and non-cardiac procedures decreased (P = 0.014, P = 0.014, P = 0.004, respectively). There was an increase in longevity in the ‘late’ vs. ‘early’ era (median survival 52.3 vs. 35.2 years, P < 0.001). The study shows that despite changes in therapy, care, and follow-up of ES in tertiary care centres, all-cause mortality including cardiac remains high. Patients from the ‘late’ era, however, die later and from chronic rather than acute cardiac causes, primarily heart failure, whereas peri-procedural and deaths due to haemoptysis have become less common. Lifelong vigilance in tertiary centres and further research for ES are clearly needed.

21 August 2019 in Heart
Verified
Journal Article
Open access
PDF file
CHCristel S Hjortshøj
Cristel S Hjortshøj
TGThomas Gilljam
Thomas Gilljam
GDGöran Dellgren
Göran Dellgren
MPMarkku O Pentikäinen
Markku O Pentikäinen
TMThomas Möller
Thomas Möller
LSLars Sondergaard
Lars Sondergaard
Objective The optimal timing for transplantation is unclear in patients with Eisenmenger syndrome (ES). We investigated post-transplantation survival and transplantation-specific morbidity after heart–lung transplantation (HLTx) or lung transplantation (LTx) in a cohort of Nordic patients with ES to aid decision-making for scheduling transplantation. Methods We performed a retrospective, descriptive, population-based study of patients with ES who underwent transplantation from 1985 to 2012. Results Among 714 patients with ES in the Nordic region, 63 (9%) underwent transplantation. The median age at transplantation was 31.9 (IQR 21.1–42.3) years. Within 30 days after transplantation, seven patients (11%) died. The median survival was 12.0 (95% CI 7.6 to 16.4) years and the overall 1-year, 5-year, 10-year and 15-year survival rates were 84.1%, 69.7%, 55.8% and 40.6%, respectively. For patients alive 1 year post-transplantation, the median conditional survival was 14.8 years (95% CI 8.0 to 21.8), with 5-year, 10-year and 15-year survival rates of 83.3%, 67.2% and 50.0%, respectively. There was no difference in median survival after HLTx (n=57) and LTx (n=6) (14.9 vs 10.6 years, p=0.718). Median cardiac allograft vasculopathy, bronchiolitis obliterans syndrome and dialysis/kidney transplantation-free survival rates were 11.2 (95% CI 7.8 to 14.6), 6.9 (95% CI 2.6 to 11.1) and 11.2 (95% CI 8.8 to 13.7) years, respectively. The leading causes of death after the perioperative period were infection (36.7%), bronchiolitis obliterans syndrome (23.3%) and heart failure (13.3%). Conclusions This study shows that satisfactory post-transplantation survival, comparable with contemporary HTx and LTx data, without severe comorbidities such as cardiac allograft vasculopathy, bronchiolitis obliterans syndrome and dialysis, is achievable in patients with ES, with a conditional survival of nearly 15 years.

5 June 2019 in Heart
Verified
Journal Article
Closed access
PDF file
VRVirginija Rudiene
Virginija Rudiene
CHCristel M S Hjortshøj
Cristel M S Hjortshøj
SGSigita Glaveckaitė
Sigita Glaveckaitė
DZDiana Zakarkaitė
Diana Zakarkaitė
ŽPŽaneta Petrulionienė
Žaneta Petrulionienė
LSLars Sondergaard
Lars Sondergaard
Background We performed a systematic review of cor triatriatum sinistrum (CTS) diagnosed in adults. The aim of this review was to describe the clinical presentation, natural history and management of this congenital heart disease. Methods A PubMed literature search for ‘cor triatriatum sinistrum’ published since 2005 was performed. Included patients were divided into those with and without obstructive membrane physiology. The clinical course differences were compared. Results A total of 171 published cases were included. The median age at diagnosis was 43 years (IQR, 30–60). Obstructive membrane physiology was observed in 70 (41%), and this patient group was younger at presentation (median age 39 (IQR, 28–52) vs 50 years (IQR, 32–64), p=0.003). Patients with obstructive membrane more frequently had associated cardiac defects (58.6% vs 42.4%, p=0.039). Overall, the most frequent clinical symptom was atrial fibrillation, as this was present in 56 (32.8%) of all patients. CTS-related symptoms were more frequent in patients with obstructive membrane: congestive heart failure (44.3% vs 15.2%, p<0.001), pulmonary hypertension (27.1% vs 6.1%, p<0.001), haemorrhage (8.6% vs 0%, p=0.004) and infections manifestation (8.6% vs 0%, p=0.004). A total of 71 (41.5%) patients with CTS required interventional treatment, mainly within patients with the obstructive membrane (86.8% vs 12.6%, p<0.001). Conclusion The natural history of CTS most often manifests with symptoms of congestive heart failure. Patients with obstructive membrane most often have associated cardiac defects and higher risk for infections and haemorrhage. The interventional treatment of CTS remains the first choice for obstructive membrane.

27 April 2017 in Heart
Verified
Journal Article
Closed access
PDF file
CHCristel Sørensen Hjortshøj
Cristel Sørensen Hjortshøj
AJAnnette Schophuus Jensen
Annette Schophuus Jensen
KSKeld Sørensen
Keld Sørensen
ENEdit Nagy
Edit Nagy
BJBengt Johansson
Bengt Johansson
LSLars Søndergaard
Lars Søndergaard
Objective Improved diagnostic tools, timely closure of the shunt and a better understanding of the complexity of Eisenmenger syndrome (ES) have led to improved care and treatment in tertiary centres. These may have decreased the incidence of ES and improved survival of patients with ES, although evidence is still lacking. The aim of this study was to investigate temporal changes in incidence, prevalence and mortality in patients with ES for 35 years in the Nordic region. Methods This was a retrospective population-based study including 714 patients with ES. Survival analysis was performed based on all-cause mortality and accounting for immortal time bias. Results The incidence of ES decreased from 2.5/million inhabitants/year in 1977 to 0.2/million inhabitants/year in 2012. Correspondingly, prevalence decreased from 24.6 to 11.9/million inhabitants. The median survival was 38.4 years, with 20-year, 40-year and 60-year survival of 72.5%, 48.4%, and 21.3%, respectively. Complex lesions and Down syndrome were independently associated with worse survival (HR 2.2, p<0.001 and HR 1.8, p<0.001, respectively). Age at death increased from 27.7 years in the period from 1977 to 1992, to 46.3 years from July 2006 to 2012 (p<0.001). Conclusions The incidence and prevalence of ES in the Nordic region have decreased markedly during the last decades. Furthermore, the median age at death increased throughout the study period, indicating prolonged life expectancy in the ES population. However, increasing age represents decreased incidence, rather than improved survival. Nonetheless, longevity with ES is still shorter than in the background population.

14 December 2020 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Closed access
PDF file
IGIben Katinka Greiber
Iben Katinka Greiber
AMAnders Pretzmann Mikkelsen
Anders Pretzmann Mikkelsen
MKMona Aarenstrup Karlsen
Mona Aarenstrup Karlsen
LSLone Storgaard
Lone Storgaard
JVJakob Viuff
Jakob Viuff
ØLØjvind Lidegaard
Øjvind Lidegaard